South San Francisco, CA 2/10/11—Microfluidics company Fluidigm has completed its IPO (see IBO 12/15/10), offering 5,558,333 shares of common stock at a public price of $13.50 per share. Last month, Fluidigm announced that pricing would be $13.50–$15.50 (see IBO 1/31/11). The underwriters have been granted a right to purchase up to an additional 833,750 shares […]
This year’s LabAutomation was the debut conference for the Society for Laboratory Automation and Screening (SLAS). Formed in July 2010 by the merger of the Association for Laboratory Automation and the Society for Biomolecular Sciences, the SLAS was created to take advantage of the organizations’ shared resources and opportunities, including global expansion and member diversity. […]
Washington, DC 2/7/11; Orange County, CA 2/7/11—Danaher has definitely agreed to purchase diagnostic and life science technology firm Beckman Coulter. Danaher will acquire all of Beckman Coulter’s outstanding common stock for $83.50 per share in cash, which is a 45% premium over the closing price on December 9, 2010, when rumors of a sale were […]
Ending two months of speculation, Danaher announced on February 7 an agreement to acquire Beckman Coulter (see page 2). The deal is valued at approximately $6.8 billion, including debt and net of cash acquired. This is approximately 1.8 times Beckman Coulter’s 2010 revenues. With the purchase, Danaher will become a major provider of in vitro […]
Pay Invoice
Latest Blogs
-
New Report Details Higher Education Science R&D Spending
February 27, 2026 3:23 pm
-
Single Use Leads Bioreactor Market Growth
December 30, 2025 6:04 pm
Sitemap
Your Data and Privacy
About Us
IBO (Instrument Business Outlook) is a twice-monthly newsletter aimed at providing decision-makers with the latest and most complete information available on the life science and analytical instrument industry, and lab product markets. IBO delivers the latest curated industry news, information and trends, as well as SDi data and analysis to deliver the maximum in industry insight with a minimum time investment for executives and investors.
